Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Novavax, Inc. (Nasdaq: NVAX) announced it will report its fourth quarter and full year 2025 financial results and operational highlights on Thursday, February 26, 2026, at 8:30 a.m. Eastern Time. The company will host a conference call and webcast to discuss these results, with replay details also provided.
Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Novavax, Inc. (Nasdaq: NVAX) has announced that it will report its fourth quarter and full year 2025 financial results and operational highlights on Thursday, February 26, 2026, at 8:30 a.m. ET. The company will host a conference call and webcast to discuss the results, with replay options available until early March 2026. Novavax, known for its vaccine technology, aims to maximize the impact of its Matrix-M adjuvant and R&D assets through strategic partnerships.
How Novavax Inc. (NVAX) Affects Rotational Strategy Timing
This article analyzes Novavax Inc. (NVAX) and its impact on rotational strategy timing, highlighting weak near- and mid-term sentiment but a neutral long-term outlook. It presents AI-driven trading strategies for NVAX, including position trading, momentum breakout, and risk hedging, along with detailed signal analysis. The report identifies a significant 69.5:1 risk-reward setup, targeting a 17.2% gain with minimal risk.
Assessing Novavax (NVAX) Valuation After Recent Share Price Momentum And Partnership Shifts
Novavax (NVAX) has seen recent positive share price momentum, with gains over the past day, week, month, and three months, contrasting its significant five-year decline. The stock is currently trading at a substantial discount to analyst price targets and Simply Wall St's intrinsic value model. The prevailing narrative suggests NVAX is undervalued due to ongoing cost optimization, a shift to a partnership-focused model, and improved margins, though this depends on partner milestones and sustained COVID-19 vaccine demand.
Novavax (NVAX) Is Up 5.5% After Easing Inflation Boosts Interest In Protein-Based Vaccines
Novavax (NVAX) saw its stock rise by 5.5% following softer-than-expected U.S. inflation data, which reignited interest in its protein-based vaccine platform as an alternative to mRNA technologies. Despite investor optimism and a new licensing agreement with Pfizer, the company's investment narrative still hinges on its adjuvant platform generating recurring royalties and supply revenue from partners, rather than standalone product sales. Analysts' opinions on Novavax vary widely, with some forecasting significant revenue and earnings declines, while others project a 51% upside to its current price based on a fair value of $13.11.
Novavax (NVAX) Rises As Market Takes a Dip: Key Facts
Novavax (NVAX) stock rose by 2.51% (closing at $8.97) while the broader market dipped, outperforming the S&P 500, Dow, and Nasdaq. The vaccine maker's shares have gained 0.92% over the past month, contrasting with losses in the Medical sector and S&P 500. Analysts expect a Q4 EPS of -$0.66 and revenue of $78.41 million, with full-year forecasts showing significant growth in both earnings and revenue, while the stock currently holds a Zacks Rank of #3 (Hold).
The Truth About Novavax Inc (NVAX): Comeback Story or Total Bag Fumble?
This article examines Novavax Inc (NVAX) to determine if it's a potential comeback story or a high-risk investment. It discusses the mixed sentiment around the stock, its protein-based vaccine technology, and its volatility. The piece concludes that NVAX is a speculative play for risk-tolerant investors rather than a core portfolio holding.
The Truth About Novavax Inc (NVAX): Comeback Story or Total Bag Fumble?
Novavax stock (NVAX) is experiencing renewed interest, appearing on watchlists and social media discussions as a potential biotech comeback. The article explores whether NVAX is a viable investment, highlighting its protein-based vaccine technology as an alternative to mRNA, while also cautioning about its high volatility, significant competition, and the inherent risks for investors seeking high-reward opportunities.
Novavax (NVAX) Rises As Market Takes a Dip: Key Facts
Novavax (NVAX) saw a 2.51% increase in its stock price, closing at $8.97, while the broader market indices like the S&P 500, Dow, and Nasdaq experienced slight declines. The vaccine maker is anticipated to report an EPS of -$0.66 and revenue of $78.41 million in its upcoming earnings release. Novavax currently holds a Zacks Rank of #3 (Hold) within the Medical - Biomedical and Genetics industry.
Human Vaccine Adjuvants Market Forecast with Size and Share Analysis 2026 to 2035
The Human Vaccine Adjuvants Market is projected to grow from USD 4.16 billion in 2025 to USD 5.62 billion by 2035, exhibiting a CAGR of 3.2%. This growth is driven by the rising incidence of infectious diseases, advancements in vaccine technology, and increasing global focus on personalized medicine. North America currently leads the market, while high development costs pose a significant challenge.
Allianz Asset Management GmbH Acquires 872,987 Shares of Novavax, Inc. $NVAX
Allianz Asset Management GmbH significantly increased its stake in Novavax, Inc. by 162.6% in the third quarter, purchasing 872,987 additional shares to bring its total holding to 1,409,734 shares valued at $12.22 million. This acquisition means Allianz now owns approximately 0.87% of the biopharmaceutical company. Despite missing analyst consensus on EPS, Novavax reported revenue that topped estimates, and the stock currently holds an average analyst rating of "Hold" with a $11.25 price target.
(NVAX) and the Role of Price-Sensitive Allocations
This article provides an AI-driven analysis of Novavax Inc. (NVAX), highlighting weak near-term sentiment and a mid-channel oscillation pattern. It presents three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal analysis, support, and resistance levels for NVAX.
Novavax, Inc. (NVAX) Stock Analysis: Assessing a 48% Potential Upside Amidst Market Challenges
Novavax, Inc. (NVAX) is a prominent biotechnology company focused on vaccine development, including its flagship NVX-CoV2373 vaccine. Despite challenges like negative free cash flow and revenue contraction, analysts project a potential 48% upside, with an average target price of $12.89. The stock is currently in oversold territory, and investors are advised to monitor strategic developments and regulatory milestones due to the speculative nature of the opportunity.
Why Novavax (NVAX) Dipped More Than Broader Market Today
Novavax (NVAX) stock fell 3.68% to $8.37, underperforming the broader market indices like the S&P 500, Dow, and Nasdaq. The company is set to release its earnings, with analysts expecting an EPS of -$0.66 and revenue of $78.41 million for the upcoming quarter, along with significant annual growth predictions. Novavax currently holds a Zacks Rank of #3 (Hold) within the Medical - Biomedical and Genetics industry.
Pfizer Taps Novavax Matrix-M To Refresh Vaccine Growth Story
Pfizer has entered a global licensing agreement with Novavax to utilize its Matrix-M adjuvant technology for the development of up to two infectious disease vaccines. This deal grants Pfizer non-exclusive worldwide rights and full control over the research, development, and commercialization of these vaccine candidates, and includes upfront payments, potential future milestone payments, and tiered royalties. The agreement is seen as a strategic move to diversify Pfizer's vaccine pipeline beyond COVID-19 and leverage external science for future vaccine franchises, while investors will track its progress amid existing risks for PFE.
Novavax COVID-19 vaccine approved by the FDA
The article reports that the Novavax COVID-19 vaccine has received approval from the FDA. This indicates a new option for vaccination against the virus.
Assessing Novavax’s (NVAX) Valuation After Its New Matrix M Licensing Agreement With Pfizer
Novavax (NVAX) is experiencing renewed interest following a non-exclusive licensing agreement with Pfizer for its Matrix M adjuvant. Despite recent stock gains, long-term shareholders have faced significant losses. Analysts currently value NVAX as undervalued, with a consensus price target of $12.5, though this hinges on future regulatory and commercial milestones and sustained COVID vaccine demand.
Novavax (NASDAQ:NVAX) Lowered to Sell Rating by Wall Street Zen
Wall Street Zen has downgraded Novavax (NASDAQ:NVAX) to a "sell" rating from a "hold." Despite mixed analyst ratings, the consensus remains "Hold" with an average price target of $11.25, while shares trade around $8.85. The company reported a Q4 EPS miss and high leverage, with a negative return on equity.
BofA Notes Positive Interest in Novavax, Inc. (NVAX) Technology Despite Timing Concerns for Licensed Assets
BofA has raised its price target for Novavax, Inc. (NVAX) to $7 from $6 but maintains an "Underperform" rating, despite a positive non-exclusive licensing deal with Pfizer for its Matrix-M adjuvant. The firm views the agreement as a sign of interest in Novavax's technology but remains cautious about the timing of asset development under the license. Strong bullish options activity was observed for NVAX, indicating significant upside positioning ahead of predicted earnings.
How Pfizer’s Novavax Matrix-M Deal and GIST Breakthrough (PFE) Has Changed Its Investment Story
Pfizer recently secured a non-exclusive license for Novavax’s Matrix-M adjuvant technology and received FDA Breakthrough Therapy Designation for a gastrointestinal stromal tumor regimen. These strategic moves aim to bolster Pfizer's oncology presence and vaccine development capabilities, reflecting efforts to diversify beyond declining COVID revenue and upcoming patent expirations. While the Novavax deal is not expected to significantly impact near-term revenues, it aligns with Pfizer's long-term strategy of leveraging external innovation to maintain growth and investor confidence, especially concerning its dividend and cash generation.
BofA Notes Positive Interest in Novavax, Inc. (NVAX) Technology Despite Timing Concerns for Licensed Assets
Bank of America (BofA) has increased its price target for Novavax (NVAX) to $7 from $6, maintaining an "Underperform" rating, following Novavax's non-exclusive licensing deal with Pfizer for its Matrix-M adjuvant. While BofA views the agreement as a positive indicator of interest in Novavax's technology, concerns persist regarding the timing of development for licensed assets. The article also notes strong bullish options activity for NVAX, with call trading significantly increasing ahead of its anticipated February earnings.
This Beaten-Down Biotech Is Showing Signs of Life. Is It a Buy?
Novavax, a vaccine maker, has seen its shares rise 28% in 2026 after signing a nonexclusive licensing deal with Pfizer for its Matrix-M adjuvant technology, which could yield up to $530 million. Despite this, the biotech's core business in coronavirus vaccines remains uncertain due to inconsistent revenue and changing regulatory recommendations. The article advises against buying Novavax stock due to the uncertainties surrounding its core business, the efficacy of pipeline products using its technology, and setbacks in its internal vaccine development.
Here's Why Novavax (NVAX) Fell More Than Broader Market
Novavax (NVAX) shares dropped by 6.07% in the latest trading session, underperforming the broader S&P 500. Despite this daily dip, the vaccine maker's stock has seen a significant 46.13% gain over the past month. Investors are now looking ahead to its upcoming earnings report, with Zacks estimates predicting a decrease in EPS and revenue year-over-year.
Novavax, Inc. (NASDAQ:NVAX) Given Average Rating of "Hold" by Analysts
Novavax, Inc. (NASDAQ:NVAX) has received an average "Hold" rating from nine research firms, with an average 12-month price target of $11.25. The company recently reported Q4 EPS of ($1.25), missing analyst estimates, while revenue exceeded expectations at $70.45 million but was down 16.7% year-over-year. Institutional investors hold approximately 53.04% of the stock.
Responsive Playbooks and the NVAX Inflection
Novavax Inc. (NVAX) shows strong near and mid-term sentiment, potentially extending to the long term, though no clear price positioning has been identified. The article provides AI-generated institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels. Elevated downside risk is noted due to a lack of additional long-term support signals.
What's Driving the Market Sentiment Around Novavax Inc?
Novavax Inc's short interest has increased by 4.06% since its last report, with 54.72 million shares sold short, representing 33.8% of its tradable shares. This makes Novavax's short interest significantly higher than its peer group average of 12.34%, suggesting a more bearish market sentiment towards the stock. It would take traders an average of 17.0 days to cover their short positions.
Novavax (NASDAQ:NVAX) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen has upgraded Novavax (NASDAQ:NVAX) stock rating from "sell" to "hold". This upgrade contributes to an overall "Hold" rating for the company, with an average price target of $11.25, while the stock traded at $9.17 midday. Novavax recently reported quarterly EPS of ($1.25), missing estimates, but revenue of $70.45 million exceeded expectations.
Novavax Pfizer Licensing Deal Puts Matrix M And Valuation In Focus
Novavax has signed a licensing agreement with Pfizer, allowing Pfizer to use Novavax's Matrix-M adjuvant technology in up to two infectious disease areas. This deal includes upfront payments, potential future milestone payments, and royalties, signaling industry validation for Novavax's platform and opening new revenue streams. The agreement shifts investor focus to Novavax's core business as an adjuvant developer, while the financial impact will depend on Pfizer's progress with programs utilizing Matrix-M.
Novavax (NVAX) Stock Dips While Market Gains: Key Facts
Novavax (NVAX) shares dropped 1.97% to $9.71 in its latest session, underperforming the broader market gains. Despite this recent dip, the vaccine maker's stock has seen a 42.65% appreciation over the past month, surpassing its sector and the S&P 500. Investors are anticipating Novavax's upcoming financial results, with projections indicating a decrease in EPS and revenue for the quarter, but a significant increase in full-year EPS and steady revenue.
Novavax, Inc.'s (NASDAQ:NVAX) Price Is Right But Growth Is Lacking After Shares Rocket 46%
Novavax's shares have surged 46% recently, but its price-to-sales ratio remains low compared to the biotech industry. This low P/S ratio is attributed to a concerning revenue forecast, with analysts predicting a 36% annual decline over the next three years, contrasting sharply with the broader industry's expected 126% growth. Despite the recent share price increase, the company's lack of growth is weighing on investor sentiment and keeping its valuation subdued.
Traders Buy Large Volume of Call Options on Novavax (NASDAQ:NVAX)
Traders bought a significantly high volume of call options for Novavax (NVAX), indicating short-term bullish sentiment, following news of a non-exclusive license agreement with Pfizer. Despite this positive development and some reiterated "buy" ratings, analysts remain divided on NVAX's outlook, with concerns about execution risks and recent revenue declines tempering optimism. Hedge funds are also split, with several increasing their stakes while others maintain a cautious stance.
Novavax Strikes Major Deal with Pfizer, Surge in Stock Likely
Novavax's stock has surged by 14.27% following a significant licensing agreement with Pfizer. The deal involves Novavax licensing its Matrix-M adjuvant for up to two disease areas, securing an upfront payment of $30 million and potential milestones up to $500 million, plus royalties. This partnership is expected to strengthen Novavax's financial position, boost investor confidence, and potentially lead to further stock price increases.
Pfizer Novavax Matrix M Deal Adds New Angle To Vaccine Story
Pfizer has entered a non-exclusive global licensing agreement with Novavax for its Matrix M vaccine adjuvant technology, allowing Pfizer to use it in vaccines for up to two infectious diseases. This deal, involving upfront, milestone, and royalty payments, aims to diversify Pfizer's vaccine portfolio beyond its current offerings and pandemic-era products. Investors should monitor how rapidly these Matrix M based programs advance through clinical trials and integrate into Pfizer's revenue stream, especially given existing concerns about Pfizer's earnings and dividend coverage.
BTIG Reiterates Buy Rating for NVAX with $19 Price Target | NVAX Stock News
BTIG has reiterated a "Buy" rating for Novavax (NVAX) and maintained its $19 price target, indicating confidence in the stock's potential. This reaffirmation comes amidst varied analyst opinions, with recent ratings showing adjustments in price targets from other firms. While the average analyst target suggests an upside, GuruFocus estimates a significant downside based on its GF Value fair value calculation.
Investor Outlook: Novavax, Inc. (NVAX) Shows Potential 59.66% Upside Despite Challenges
Novavax, Inc. (NVAX) presents a high-risk, high-reward investment opportunity in the biotechnology sector, currently trading at $8.003 with a potential 59.66% upside according to analysts. Despite current unprofitability, negative revenue growth, and cash flow challenges, the company's robust vaccine pipeline, including its COVID-19 and malaria vaccines, fuels investor interest. Technical indicators suggest near-term stability, while a mixed analyst outlook points to significant growth potential if operational hurdles are successfully navigated.
The Truth About Novavax Inc (NVAX): Comeback Season or Total Trap?
This article examines the recent resurgence of interest in Novavax (NVAX), driven by new variants and its protein-based vaccine, which offers an alternative to mRNA options. It delves into the social media hype and stock volatility surrounding NVAX, contrasting it with major competitors like Pfizer and Moderna. The author concludes that while Novavax offers a compelling story and speculative trading opportunities due to its high volatility, it is a high-risk investment and medical decisions should always be made with professional health advice.
The Truth About Novavax Inc (NVAX): Comeback Season or Total Trap?
Novavax Inc (NVAX) is generating significant buzz online due to its protein-based COVID-19 vaccine, positioning itself as an alternative to mRNA vaccines, and its highly volatile stock performance. While it offers a unique option for vaccine users and is a popular topic for traders due to dramatic price swings, the article cautions that NVAX is a high-risk, speculative investment rather than a stable long-term play. It advises consulting medical professionals for health decisions and exercising extreme caution for stock market involvement.
Understanding the Setup: (NVAX) and Scalable Risk
This article from Stock Traders Daily analyzes Novavax Inc. (NVAX) using predictive AI, highlighting a strong risk-reward setup with a potential 19.1% gain against 0.3% risk. It details three trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored to different risk profiles and provides multi-timeframe signal analysis indicating prevailing positive sentiment.
JPM26: Matrix-M Technology is central to Novavax’s strategy
Novavax's CEO outlined the company's 2026 growth strategy at the J.P. Morgan Healthcare Conference, emphasizing its Matrix-M technology, strategic partnerships, and lean operating model. The Matrix-M adjuvant, central to its Covid-19 vaccine Nuvaxovid and the R21/Matrix-M malaria vaccine, has shown significant success and market penetration. Novavax aims to expand its global vaccine market presence through material transfer agreements and continued pipeline development across various infectious diseases.
JP Morgan 2026: Novavax Shifting Towards Partnership-Driven Strategy
Novavax is pivoting to a partnership-driven strategy, focusing on monetizing its Matrix-M adjuvant platform to achieve non-GAAP profitability by 2028. The company aims for growth through diversified royalties, milestone payments from partnerships like Sanofi, and stringent cost control. Novavax is exploring new collaborations and early-stage internal programs to enhance its portfolio while maintaining financial discipline.
Improved Revenues Required Before Novavax, Inc. (NASDAQ:NVAX) Stock's 32% Jump Looks Justified
Novavax's stock has recently jumped 32%, but its price-to-sales (P/S) ratio of 1.3x remains significantly lower than the wider Biotechnology industry, suggesting the market is anticipating continued poor revenue growth. The company saw a 20% revenue increase last year, but a 42% decline over three years, with analysts forecasting a further 36% annual slump for the next three years. This weak outlook on revenue generation is likely holding down its P/S ratio, and higher revenue growth is needed to justify a substantial increase in its stock price.
NVAX: Lean, partner-focused strategy drives growth, with profitability targeted by 2028
Novavax (NVAX) has transitioned into a lean, partnership-driven biotech company, significantly reducing costs and securing royalties from global partners. The company is focusing on R&D innovation and its Matrix-M platform, aiming for non-GAAP profitability by 2028, with plans to expand into vaccine and oncology markets. This strategy was discussed during Novavax's 44th Annual J.P. Morgan Healthcare Conference.
J.P. Morgan Notebook: Novavax On US FDA Requests, Takeda’s Strategies For FDA Change
This article from the J.P. Morgan Notebook focuses on Novavax's response to US FDA requests regarding its COVID-19 vaccine data and Takeda's strategies for navigating FDA changes. Novavax's CEO confirmed that the company's plans remain on track despite the FDA's request for additional information. The piece highlights key developments affecting pharmaceutical companies and their interactions with the US Food and Drug Administration.
Novavax (NASDAQ:NVAX) Trading Down 6.1% - What's Next?
Novavax (NASDAQ:NVAX) shares dropped 6.1% on Wednesday, with trading volume significantly lower than average, indicating weak demand. The company faces mixed analyst sentiment, a "Hold" consensus rating with an average target price of $11.25, and current financial struggles including an EPS miss and declining revenue. Institutional investors have shown varied activity in Novavax stock recently.
Improved Revenues Required Before Novavax, Inc. (NASDAQ:NVAX) Stock's 32% Jump Looks Justified
Novavax's stock recently jumped 32%, but its low price-to-sales (P/S) ratio of 1.3x remains significantly below the biotech industry average, indicating underlying concerns. Despite a terrific 20% revenue increase in the last year, the company has seen a 42% decline over three years, and analysts project a further 36% annual slump for the next three years. This poor revenue outlook suggests the stock's recent rally might not be sustainable unless there's a material change in its financial performance.
Improved Revenues Required Before Novavax, Inc. (NASDAQ:NVAX) Stock's 32% Jump Looks Justified
Novavax's stock has recently jumped 32%, but its low price-to-sales (P/S) ratio of 1.3x is due to poor past and projected revenue growth compared to the biotech industry. The company's revenue fell 42% over three years, and analysts predict a further 36% annual slump, justifying the low P/S and making a sustained price increase unlikely without significant improvements. Investors and analysts suggest that improved revenue performance is essential to justify a higher valuation for the company.
Novavax, Inc. (NASDAQ:NVAX) Institutional Owners May Be Pleased With Recent Gains After 8.9% Loss Over the Past Year
Institutional investors hold a significant 52% ownership in Novavax, Inc. (NVAX), with the top 12 shareholders collectively holding 51%. The company's recent 4.2% share price increase is likely welcomed by these institutional owners, especially after an 8.9% loss over the past year. While institutions have considerable influence, the general public owns 31%, and insiders hold less than 1% of the shares.
CORRECTED: Why Is Novavax Stock Soaring?
Novavax (NASDAQ: NVAX) shares are trading higher due to a reported rise in respiratory illnesses across the United States. The CDC has noted high levels of flu and RSV activity, classifying the 2025-26 flu season as "moderately severe." The elevated respiratory illness environment is drawing increased attention to vaccine manufacturers like Novavax, which is also showing a strong technical setup in its stock performance.
Novavax’s Recent Market Movements: A Deep Dive
Novavax Inc. (NVAX) recently experienced an 11.1% stock increase due to positive trial results for its updated COVID-19 vaccine, leading to cautious market optimism. Despite promising gross margins and a competitive P/E ratio, the company faces challenges with negative pretax profit margins and ongoing regulatory hurdles. Novavax is focusing on R&D for new vaccines and potential strategic alliances to solidify its market position and drive future growth.
HHS secretary RFK Jr. adds two new members to CDC vaccine panel
HHS Secretary Robert F. Kennedy, Jr. appointed two new experts in obstetrics and gynecology to the CDC’s Advisory Committee on Immunization Practices (ACIP). The new appointees to the vaccine panel include specialist Adam Urato. This move expands the composition of the influential CDC panel.
